PMID: 2506595Jan 1, 1989Paper

Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide

Psychopharmacology
L T MeltzerW H Moos

Abstract

Muramyl dipeptide increased sleep during the dark-phase, but not the light-phase of the rats' sleep-awake cycle. This circadian variation may be due to the inability of MDP to increase sleep over the high baseline levels of sleep that occur during the light-phase. However, MDP was pyrogenic during the light-phase, indicating it was pharmacologically active. In the dark-phase, MDP was not pyrogenic, but when compared to concurrent vehicle-treated rats, rats treated with MDP did not demonstrate as great a fall in body temperature. At approximately equisomnogenic doses, MDP produced less potentiation of ethanol-induced loss of righting reflex than triazolam, indicating it produces less non-specific central nervous system depressant effects. These data indicate the possibility of a new generation of hypnotic agents derived from muramyl peptides.

References

Oct 1, 1979·The American Journal of Psychiatry·E O BixlerS Healey
May 1, 1976·Social Science & Medicine·I KaracanR L Williams
Mar 1, 1985·Archives of General Psychiatry·G D MellingerE H Uhlenhuth
May 1, 1985·Clinical Pharmacology and Therapeutics·P DorianD Abernethy
Jan 1, 1987·Annals of the New York Academy of Sciences·K Masek, O Kadlecová
Aug 1, 1985·Prostaglandins, Leukotrienes, and Medicine·A Solomonovich, J Kaplanski
Apr 1, 1986·The American Journal of Physiology·G RiveauL Chedid
Aug 19, 1974·Biochemical and Biophysical Research Communications·F EllouzE Lederer
Jun 1, 1974·Life Sciences·M C FiorettiL Martini
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·M Lader
Sep 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·L ChedidJ M Krueger
Jan 1, 1984·Reviews of Infectious Diseases·C A Dinarello
Oct 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S InouéO Hayaishi
Jan 1, 1984·Peptides·C FornalM Radulovacki
Oct 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·J M KruegerM L Karnovsky
Oct 1, 1980·The Journal of Experimental Medicine·G RiveauL Chedid

❮ Previous
Next ❯

Citations

Dec 14, 2002·Pharmacology, Biochemistry, and Behavior·Christopher G EngelandKlaus-Peter Ossenkopp
Jun 15, 1999·Progress in Neurobiology·F García-García, R Drucker-Colín
Sep 1, 1995·Acta Psychiatrica Scandinavica·D Jonsson, J Wålinder
Jan 1, 1995·Advances in Neuroimmunology·T PollmächerD Hinze-Selch
Jan 1, 1995·Advances in Neuroimmunology·J M KruegerS Novitsky
Jan 18, 2006·Psychoneuroendocrinology·Christopher G EngelandKlaus-Peter Ossenkopp
Jan 1, 1991·Neuroscience and Biobehavioral Reviews·C R Plata-Salamán
Oct 22, 2002·Expert Opinion on Pharmacotherapy·Paul J GoodnickOrlando Santana
Mar 25, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Robert O Friedel
May 27, 2008·Psychopharmacology·Renan P SouzaJames L Kennedy
Jan 1, 1993·Psychopharmacology·S SzymanskiT Cooper
Feb 22, 2000·Clinical Neuropharmacology·M KupchikM Kotler
Apr 25, 2006·The Journal of ECT·Worrawat Chanpattana, Chittaranjan Andrade
Apr 1, 1996·Infection and Immunity·C KorthT Pollmächer
Mar 26, 1998·Journal of Medicinal Chemistry·D WustrowL Wise

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.